FDA Won’t Widen US Merck's Zetia, Vytorin Use

By a vote of ten to five, an advisory panel of the US Food and Drug Administration (FDA) has rejected an application by Merck & Co of the US to widen the indication of its cholesterol franchise.

Following positive results of the IMPROVE-IT study with 18,000 patients, the US drugmaker had sought to recommend its Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin combined) for prevention of heart attacks and stroke. The company claimed the medicines reduce the risk of “cardiovascular events” in patients with coronary heart disease.

Although some of the FDA review panel members thought the benefits of the two drugs were significant, the majority concluded that the overall reduction risk was small and limited to certain types of patients, particularly the elderly and diabetics.

The consensus was that 50 people would need to take Zetia along with a statin for seven years to prevent just one of the cardiovascular events that made up the trial's primary endpoint.

Merck said it was reviewing the drug authority’s complete response letter before determining its next course of action.

Some outside commentators said they thought the FDA’s rejection of the Merck application – it was the final instance – could dampen the outlook for an upcoming generation of PCSK9 cholesterol-reducing preparations such as Amgen’s Repatha and Sanofi-Regeneron’s Praluent.

Analysts had expected the two new drugs to benefit from the outcome of the IMPROVE-IT study, which showed that an add-on, non-statin drug can cut cardiovascular risks by delivering bigger reductions in LDL cholesterol levels.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.